Merck Tbk
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. The company operates through Biopharma, Consumer Health, and Others segments. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in research an… Read more
Merck Tbk (MERK) - Net Assets
Latest net assets as of September 2025: Rp833.21 Billion IDR
Based on the latest financial reports, Merck Tbk (MERK) has net assets worth Rp833.21 Billion IDR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp987.93 Billion) and total liabilities (Rp154.71 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp833.21 Billion |
| % of Total Assets | 84.34% |
| Annual Growth Rate | 9.24% |
| 5-Year Change | 31.76% |
| 10-Year Change | 70.48% |
| Growth Volatility | 13.7 |
Merck Tbk - Net Assets Trend (2000–2024)
This chart illustrates how Merck Tbk's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Merck Tbk (2000–2024)
The table below shows the annual net assets of Merck Tbk from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp807.27 Billion | +1.43% |
| 2023-12-31 | Rp795.88 Billion | +5.10% |
| 2022-12-31 | Rp757.24 Billion | +10.70% |
| 2021-12-31 | Rp684.04 Billion | +11.65% |
| 2020-12-31 | Rp612.68 Billion | +3.14% |
| 2019-12-31 | Rp594.01 Billion | +14.61% |
| 2018-12-31 | Rp518.28 Billion | -15.79% |
| 2017-12-31 | Rp615.44 Billion | +5.62% |
| 2016-12-31 | Rp582.67 Billion | +23.05% |
| 2015-12-31 | Rp473.54 Billion | -14.48% |
| 2014-12-31 | Rp553.69 Billion | +8.10% |
| 2013-12-31 | Rp512.22 Billion | +22.91% |
| 2012-12-31 | Rp416.74 Billion | -15.67% |
| 2011-12-31 | Rp494.18 Billion | +36.13% |
| 2010-12-31 | Rp363.02 Billion | +2.49% |
| 2009-12-31 | Rp354.18 Billion | +8.21% |
| 2008-12-31 | Rp327.32 Billion | +16.80% |
| 2007-12-31 | Rp280.23 Billion | +18.95% |
| 2006-12-31 | Rp235.58 Billion | +30.60% |
| 2005-12-31 | Rp180.38 Billion | +17.10% |
| 2004-12-31 | Rp154.04 Billion | -3.43% |
| 2003-12-31 | Rp159.51 Billion | +6.88% |
| 2002-12-31 | Rp149.25 Billion | +17.06% |
| 2001-12-31 | Rp127.49 Billion | +31.63% |
| 2000-12-31 | Rp96.86 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Merck Tbk's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1272.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rp762.83 Billion | 94.49% |
| Common Stock | Rp22.40 Billion | 2.77% |
| Other Comprehensive Income | Rp4.48 Billion | 0.55% |
| Other Components | Rp17.56 Billion | 2.18% |
| Total Equity | Rp807.27 Billion | 100.00% |
Merck Tbk Competitors by Market Cap
The table below lists competitors of Merck Tbk ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Array Inc
TWO:3664
|
$11.43 Million |
|
Curvebeam Ai Ltd
AU:CVB
|
$11.44 Million |
|
S. Khonkaen Foods Public Company Limited
BK:SORKON
|
$11.44 Million |
|
Paz Oil
TA:PZOL
|
$11.44 Million |
|
Twenty-Four Con & Supply PCL
BK:24CS
|
$11.43 Million |
|
Sat Nusapersada Tbk
JK:PTSN
|
$11.43 Million |
|
Jade Gas Holdings Ltd
AU:JGH
|
$11.42 Million |
|
Argenica Therapeutics Ltd
AU:AGN
|
$11.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Merck Tbk's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 795,878,793,000 to 807,273,556,000, a change of 11,394,763,000 (1.4%).
- Net income of 153,463,416,000 contributed positively to equity growth.
- Dividend payments of 142,908,910,000 reduced retained earnings.
- Other comprehensive income increased equity by 4,480,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp153.46 Billion | +19.01% |
| Dividends Paid | Rp142.91 Billion | -17.7% |
| Other Comprehensive Income | Rp4.48 Billion | +0.55% |
| Other Changes | Rp-3.64 Billion | -0.45% |
| Total Change | Rp- | 1.43% |
Book Value vs Market Value Analysis
This analysis compares Merck Tbk's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.73x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.72x to 1.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | Rp402.59 | Rp3110.00 | x |
| 2006-12-31 | Rp525.76 | Rp3110.00 | x |
| 2007-12-31 | Rp625.50 | Rp3110.00 | x |
| 2008-12-31 | Rp730.63 | Rp3110.00 | x |
| 2009-12-31 | Rp790.59 | Rp3110.00 | x |
| 2010-12-31 | Rp810.31 | Rp3110.00 | x |
| 2011-12-31 | Rp1103.08 | Rp3110.00 | x |
| 2012-12-31 | Rp930.23 | Rp3110.00 | x |
| 2013-12-31 | Rp1143.35 | Rp3110.00 | x |
| 2014-12-31 | Rp1235.92 | Rp3110.00 | x |
| 2015-12-31 | Rp1060.00 | Rp3110.00 | x |
| 2016-12-31 | Rp1300.61 | Rp3110.00 | x |
| 2017-12-31 | Rp1373.74 | Rp3110.00 | x |
| 2018-12-31 | Rp1156.88 | Rp3110.00 | x |
| 2019-12-31 | Rp1325.92 | Rp3110.00 | x |
| 2020-12-31 | Rp1367.60 | Rp3110.00 | x |
| 2021-12-31 | Rp1526.88 | Rp3110.00 | x |
| 2022-12-31 | Rp1690.27 | Rp3110.00 | x |
| 2023-12-31 | Rp1776.52 | Rp3110.00 | x |
| 2024-12-31 | Rp1801.95 | Rp3110.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Merck Tbk utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.01%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.80%
- • Asset Turnover: 1.08x
- • Equity Multiplier: 1.19x
- Recent ROE (19.01%) is below the historical average (37.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 50.97% | 26.86% | 1.42x | 1.34x | Rp39.68 Billion |
| 2001 | 44.24% | 25.17% | 1.38x | 1.28x | Rp43.65 Billion |
| 2002 | 25.08% | 16.94% | 1.28x | 1.15x | Rp22.50 Billion |
| 2003 | 31.71% | 17.07% | 1.48x | 1.26x | Rp34.63 Billion |
| 2004 | 37.16% | 15.33% | 1.86x | 1.30x | Rp41.84 Billion |
| 2005 | 31.99% | 14.93% | 1.77x | 1.21x | Rp39.66 Billion |
| 2006 | 36.74% | 17.75% | 1.72x | 1.20x | Rp62.98 Billion |
| 2007 | 31.93% | 16.35% | 1.65x | 1.18x | Rp61.46 Billion |
| 2008 | 30.13% | 15.48% | 1.70x | 1.15x | Rp65.89 Billion |
| 2009 | 41.42% | 19.52% | 1.73x | 1.23x | Rp111.28 Billion |
| 2010 | 32.72% | 14.93% | 1.83x | 1.20x | Rp82.49 Billion |
| 2011 | 46.78% | 25.17% | 1.57x | 1.18x | Rp181.74 Billion |
| 2012 | 25.87% | 11.59% | 1.63x | 1.37x | Rp66.13 Billion |
| 2013 | 34.25% | 14.69% | 1.71x | 1.36x | Rp124.22 Billion |
| 2014 | 32.78% | 21.02% | 1.20x | 1.29x | Rp126.10 Billion |
| 2015 | 30.10% | 14.49% | 1.53x | 1.35x | Rp95.19 Billion |
| 2016 | 26.40% | 14.87% | 1.39x | 1.28x | Rp95.58 Billion |
| 2017 | 23.51% | 12.51% | 1.37x | 1.38x | Rp83.13 Billion |
| 2018 | 224.46% | 190.10% | 0.48x | 2.44x | Rp1.11 Trillion |
| 2019 | 13.17% | 10.51% | 0.83x | 1.52x | Rp18.86 Billion |
| 2020 | 11.74% | 10.96% | 0.71x | 1.52x | Rp10.63 Billion |
| 2021 | 19.25% | 12.37% | 1.04x | 1.50x | Rp63.26 Billion |
| 2022 | 23.75% | 15.99% | 1.08x | 1.37x | Rp104.11 Billion |
| 2023 | 22.40% | 18.54% | 1.00x | 1.20x | Rp98.65 Billion |
| 2024 | 19.01% | 14.80% | 1.08x | 1.19x | Rp72.74 Billion |
Industry Comparison
This section compares Merck Tbk's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,330,118,878,565
- Average return on equity (ROE) among peers: 19.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Merck Tbk (MERK) | Rp833.21 Billion | 50.97% | 0.19x | $11.43 Million |
| Darya-Varia Laboratoria Tbk (DVLA) | $1.20 Trillion | 16.72% | 0.40x | $8.73 Million |
| Indofarma Tbk (INAF) | $292.57 Billion | 37.70% | 0.84x | $4.64 Million |
| Phapros Tbk PT (PEHA) | $821.61 Billion | 12.42% | 1.55x | $4.70 Million |
| Pyridam Farma Tbk (PYFA) | $118.93 Billion | 7.10% | 0.57x | $76.03 Million |
| Sido Muncul PT (SIDO) | $2.90 Trillion | 22.87% | 0.15x | $192.60 Million |
| Tempo Scan Pacific Tbk (TSPC) | $2.64 Trillion | 18.49% | 0.36x | $70.32 Million |